Nature of Business and Accounting Policies - Business (Details) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016 USD ($) marketed_medecine $ / shares	Sep. 30, 2016 USD ($) $ / shares	Jun. 30, 2016 USD ($) $ / shares	Mar. 31, 2016 USD ($) $ / shares	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) segment marketed_medecine $ / shares	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2014 USD ($) $ / shares
Valuation and Qualifying Accounts Disclosure [Line Items]
Customer deposits	$ 73,416				$ 0				$ 73,416	$ 0
Number of marketed medicines | marketed_medecine	2								2
Accounts receivable, net	$ 201,083				173,838				$ 201,083	173,838
Net loss	$ 27,759	$ (39,537)	$ (36,151)	$ (36,102)	$ (74,669)	$ (93,816)	$ (220,992)	$ (198,704)	$ (84,031)	$ (588,181)	$ (742,745)
Basic EPS (usd per share) | $ / shares	$ 0.13	$ (0.16)	$ (0.26)	$ (0.17)					$ (0.46)	$ (2.31)	$ (3.14)
Cash, cash equivalents and marketable securities	$ 1,430,000								$ 1,430,000
Number of operating segments | segment									1
Advertising expense									$ 31,400	$ 24,500	$ 16,200
Accumulated Deficit
Valuation and Qualifying Accounts Disclosure [Line Items]
Net loss									(112,052)	$ (556,334)	$ (738,555)
Greece, Italy, Portugal and Spain
Valuation and Qualifying Accounts Disclosure [Line Items]
Accounts receivable, net	$ 0								$ 0